Adenomatous polyposis coli – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 13 Jun 2026 04:03:39 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Adenomatous polyposis coli – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study testing sirolimus to slow disease progression in patients with familial adenomatous polyposis https://clinicaltrials.eu/trial/a-study-testing-sirolimus-to-slow-disease-progression-in-patients-with-familial-adenomatous-polyposis/ Thu, 30 Apr 2026 13:08:18 +0000 https://clinicaltrials.eu/trial/a-study-testing-sirolimus-to-slow-disease-progression-in-patients-with-familial-adenomatous-polyposis/ This study is looking at a condition called familial adenomatous polyposis, which is a genetic disorder where numerous growths called polyps develop in the digestive tract, particularly in the large intestine and small intestine. People with this condition are at high risk of these polyps turning into cancer if left untreated. The study will test a medication called eRapa, which contains the active ingredient sirolimus, also known as rapamycin. Some participants will receive eRapa capsules taken by mouth, while others will receive placebo capsules that look identical but contain no active medication.

The purpose of this study is to find out if eRapa treatment can slow down disease progression in patients with familial adenomatous polyposis. Disease progression in this study means serious events related to the condition, such as the development of cancer, the presence of severely abnormal cells called high-grade dysplasia, the need for major surgery to remove parts of the intestine or digestive tract, or death from any cause. The study will also examine how eRapa affects the total size of polyps in both the upper digestive tract, specifically the duodenum, and the lower digestive tract, which includes the colon and any remaining portions of the rectum or surgically created pouch. Additionally, the study will track changes in polyp characteristics using a scoring system called the Spigelman stage score.

During the study, participants will take their assigned medication daily for up to 132 weeks, which is approximately two and a half years. They will undergo regular examinations using endoscopy, which is a procedure where a flexible tube with a camera is used to look inside the digestive tract, at various time points including 6, 12, 18, 24, 30, and 36 months. The study will monitor participants for any unwanted effects of the treatment and will measure how the treatment affects their quality of life using questionnaires. The study will also track how many participants need to stop taking the medication due to side effects.

]]> Study on the Safety of Sirolimus for Children with Familial Adenomatous Polyposis https://clinicaltrials.eu/trial/study-on-the-safety-of-sirolimus-for-children-with-familial-adenomatous-polyposis/ Wed, 29 Apr 2026 14:59:36 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-sirolimus-for-children-with-familial-adenomatous-polyposis/ This clinical trial is focused on studying the safety of a medication called Rapamycin in children who have a condition known as Familial Adenomatous Polyposis. Familial Adenomatous Polyposis is a genetic disorder that causes the growth of numerous polyps in the colon and rectum, which can lead to cancer if not treated. The medication being tested, Rapamycin, is taken in the form of coated tablets and is intended to help manage this condition.

The purpose of the study is to evaluate how safe Rapamycin is for adolescents aged 12 to 17 who have been diagnosed with Familial Adenomatous Polyposis. Participants in the study will receive one of two doses of Rapamycin. Throughout the study, the safety of the medication will be closely monitored by checking for any adverse events, which are unwanted effects that might occur during or after taking the medication. The study will also involve regular colonoscopies, which are procedures that allow doctors to look inside the colon to see how the polyps are changing over time.

The study will last for several months, during which participants will take Rapamycin and undergo various assessments to ensure their safety and to observe any changes in the polyps. The results from these assessments will help researchers understand the safety profile of Rapamycin in treating Familial Adenomatous Polyposis in young patients. This information could be valuable in developing effective treatments for this condition in the future.

]]>